Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
BOUNCE is an international multicentre randomised phase II trial. The trial treatment
consists of brigatinib 180 mg once daily p.o., with seven day lead-in at 90 mg once daily,
for 3 years or until progression of disease. The primary objective of this trial is to
evaluate the efficacy in terms of progression-free survival (PFS) for brigatinib
consolidation, compared to observation/durvalumab, in patients with unresectable stage III
NSCLC and ALK-rearrangement who completed definitive chemo-radiotherapy without disease
progression.